Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
Holding KURA?
Track your performance easily
See the Price Targets and Ratings of:
KURA Analyst Ratings
Strong Buy
9 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
KURA Stock 12 Month Forecast
Average Price Target
$28.50
▲(79.02% Upside)
| Highest Price Target$35.00 | Average Price Target$28.50 | Lowest Price Target$18.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
Reiterated
11/12/24
LifeSci Capital
Reiterated
11/12/24
Leerink Partners
Reiterated
11/12/24
Bank of America Securities
Assigned
11/08/24
TD Cowen
Assigned
11/08/24
Scotiabank
Reiterated
11/08/24
Stifel Nicolaus
Reiterated
11/08/24
Barclays
Reiterated
11/08/24
Mizuho Securities
Reiterated
11/08/24
JMP Securities
Reiterated
11/08/24
UBS
$27
Buy
69.60%
Upside
Initiated
10/24/24
Kura Oncology initiated with a Buy at UBSKura Oncology initiated with a Buy at UBS
BTIG
$32
Buy
101.01%
Upside
Reiterated
08/09/24
Buy Rating Affirmed for Kura Oncology Amid Positive Clinical and Financial Developments
Jefferies
$32
Buy
101.01%
Upside
Reiterated
02/27/24
We caught up with mgmt after earnings, and we have a few key takes: 1) KOMET-007 is on track, with safety/tolerability as key. No DS from the last -007 readout was positive sign and Co made clear zifto is neither a CYP3A4 substrate nor an inhibitor, which differentiates it from key comp and is key in combo w Ven+azoles. 2) KOMET-001 enrollment to complete by mid'24. 3) KOMET-008 dosing started. Co had $570M pro forma cash, with runway expected into 2027.
Brookline Capital Markets
$31→$36
Buy
126.13%
Upside
Reiterated
01/02/24
Kura Oncology (KURA) PT Raised to $36 at Brookline Capital MarketsBrookline Capital Markets analyst Lee Rush Cann raised the price target on Kura Oncology (NASDAQ: KURA) to $36.00 (from $31.00) while maintaining a Buy rating.
Unknown Analyst
Not Ranked
Wedbush
$37
Buy
132.41%
Upside
Reiterated
08/09/24
Best Analysts Covering Kura Oncology
Which Analyst Should I Follow If I Want to Buy KURA and Sell After:
1 Month
xxx
Success Rate
13/15 ratings generated profit
Average Return
+5.79%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 86.67% of your transactions generating a profit, with an average return of +5.79% per trade.
3 Months
xxx
Success Rate
25/42 ratings generated profit
Average Return
+11.91%
reiterated a xxx
rating 11 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 59.52% of your transactions generating a profit, with an average return of +11.91% per trade.
1 Year
Success Rate
10/16 ratings generated profit
Average Return
+34.66%
reiterated a buy rating 4 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +34.66% per trade.
2 Years
xxx
Success Rate
27/42 ratings generated profit
Average Return
+33.87%
reiterated a xxx
rating 11 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 64.29% of your transactions generating a profit, with an average return of +33.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
KURA Analyst Recommendation Trends
Rating
May 24
Jun 24
Aug 24
Oct 24
Nov 24
Strong Buy
7
12
18
15
18
Buy
5
5
7
3
5
Hold
1
1
2
2
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
18
27
20
27
Each month's total comprises the sum of three months' worth of ratings.
KURA Financial Forecast
KURA Stock Forecast FAQ
What is KURA’s average 12-month price target, according to analysts?
Based on analyst ratings, Kura Oncology’s 12-month average price target is $28.50.
What is KURA’s upside potential, based on the analysts’ average price target?
Kura Oncology has 79.02% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KURA a Buy, Sell or Hold?
Kura Oncology has a consensus rating of Strong Buy which is based on 9 buy ratings, 2 hold ratings and 0 sell ratings.
What is Kura Oncology’s price target?
The average price target for Kura Oncology is $28.50. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $18.00. The average price target represents 79.02% Increase from the current price of $15.92.
The highest analyst price target is $35.00 ,the lowest forecast is $18.00. The average price target represents 79.02% Increase from the current price of $15.92.
What do analysts say about Kura Oncology?
Kura Oncology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of KURA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.